company background image
CRDF

Cardiff Oncology NasdaqCM:CRDF Stock Report

Last Price

US$1.75

Market Cap

US$78.2m

7D

0.6%

1Y

-45.8%

Updated

03 Feb, 2023

Data

Company Financials +

Cardiff Oncology, Inc.

NasdaqCM:CRDF Stock Report

Mkt Cap: US$78.2m

CRDF Stock Overview

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.

CRDF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Cardiff Oncology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cardiff Oncology
Historical stock prices
Current Share PriceUS$1.75
52 Week HighUS$3.56
52 Week LowUS$1.13
Beta1.6
1 Month Change12.90%
3 Month Change23.24%
1 Year Change-45.82%
3 Year Change-4.37%
5 Year Change-93.90%
Change since IPO-99.89%

Recent News & Updates

Recent updates

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year

Dec 02
Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year

Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market

Nov 24

Shareholder Returns

CRDFUS BiotechsUS Market
7D0.6%-0.3%1.7%
1Y-45.8%5.3%-9.1%

Return vs Industry: CRDF underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: CRDF underperformed the US Market which returned -9.1% over the past year.

Price Volatility

Is CRDF's price volatile compared to industry and market?
CRDF volatility
CRDF Average Weekly Movement11.2%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CRDF is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CRDF's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199923Mark Erlanderhttps://www.cardiffoncology.com

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company’s TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.

Cardiff Oncology, Inc. Fundamentals Summary

How do Cardiff Oncology's earnings and revenue compare to its market cap?
CRDF fundamental statistics
Market CapUS$78.19m
Earnings (TTM)-US$39.47m
Revenue (TTM)US$391.00k

200.0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRDF income statement (TTM)
RevenueUS$391.00k
Cost of RevenueUS$17.84m
Gross Profit-US$17.44m
Other ExpensesUS$22.03m
Earnings-US$39.47m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.88
Gross Margin-4,461.64%
Net Profit Margin-10,095.40%
Debt/Equity Ratio0%

How did CRDF perform over the long term?

See historical performance and comparison